Anal Fissure Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

An anal fissure is a small tear or split in the thin, moist tissue (mucosa) lining the anal canal — the final 2 to 4 cm of the gastrointestinal tract before the anus. Fissures typically occur in the posterior midline (at the 6 o'clock position in the lithotomy position) in approximately 90% of cases, and less commonly in the anterior midline, particularly in women after childbirth. Fissures in atypical lateral positions should raise suspicion for an underlying condition such as Crohn's disease, tuberculosis, syphilis, or HIV-associated disease.

The condition is extremely common, affecting people of all ages but most frequently adults aged 20 to 40 years. Anal fissures cause severe, burning perianal pain during and after defaecation — often described as passing razor blades — accompanied by bright red bleeding on the toilet paper or in the toilet bowl. The pain triggers a spasm of the internal anal sphincter, which in turn reduces blood flow to the posterior anal mucosa, impairing healing and perpetuating the fissure in a well-recognised vicious cycle of pain, spasm, and ischaemia.

Fissures are classified as acute (duration less than 6 weeks) or chronic (greater than 6 weeks). Chronic fissures develop characteristic features including a sentinel skin tag at the external anal verge, a hypertrophied anal papilla at the proximal end of the fissure, and exposed fibres of the internal anal sphincter at the base of the wound. These features indicate established sphincter spasm and poor tissue perfusion that make spontaneous healing unlikely without active intervention.

Treatment aims to relax the internal anal sphincter, restore normal blood flow to the fissure bed, and allow mucosal healing. This can be achieved through dietary modification, pharmacological sphincter relaxants applied topically, injection of botulinum toxin, or surgical division of the internal sphincter (lateral internal sphincterotomy). The stepwise approach begins with conservative measures and progresses to surgical intervention only in cases refractory to medical management.

Understanding the type and cause of anal fissure is essential for selecting the appropriate treatment strategy.

• Primary (Idiopathic) Fissures: The vast majority of anal fissures are primary — arising without a specific identifiable underlying disease. They result from trauma to the anal mucosa caused by passage of hard or large-calibre stool, prolonged constipation, or paradoxically, recurrent loose stools and diarrhoea causing repeated mucosal trauma. The posterior midline position is predisposed because of the relatively poor vascular supply at this location compared to other areas of the anal canal.
• Acute Fissures: Acute fissures appear as a fresh linear or oval tear with clean, well-defined edges and no secondary fibrotic features. They resemble a simple paper cut in the anal mucosa. With simple dietary and hygiene measures, up to 50% of acute fissures heal spontaneously within 4 to 6 weeks.
• Chronic Fissures: A fissure is defined as chronic when it persists beyond 6 weeks and develops secondary features: a sentinel pile (external skin tag), hypertrophied anal papilla (internal skin tag), and exposed internal anal sphincter fibres at the fissure base. The fissure becomes a fixed, indurated wound that will not heal without pharmacological or surgical intervention to break the sphincter spasm cycle.
• Secondary Fissures (Associated Conditions): Fissures in atypical positions, multiple simultaneous fissures, fissures with irregular or undermined edges, or fissures in the context of systemic illness should prompt investigation for secondary causes including Crohn's disease (the most common association), ulcerative colitis, sexually transmitted infections (syphilis, herpes simplex, gonorrhoea), HIV, tuberculosis, and anal cancer. Secondary fissures are managed by treating the underlying systemic condition in addition to local fissure care.
• Post-partum Fissures: Anterior fissures in women are frequently associated with vaginal delivery and obstetric perineal trauma. These tend to heal well with conservative management but may recur with subsequent deliveries.

All patients with symptomatic anal fissures benefit from some form of treatment. The level of intervention is determined by the duration of the fissure, severity of symptoms, and response to initial management.

• Acute Fissures (Less Than 6 Weeks): All patients with acute fissures should commence conservative management immediately — dietary fibre supplementation, adequate fluid intake, topical anaesthetic ointments, and warm sitz baths. Up to 50% of acute fissures resolve within 4 to 8 weeks with these measures. Pharmacological sphincter relaxants (topical glyceryl trinitrate or diltiazem) are added to improve healing rates to 60 to 80%.
• Chronic Fissures (Greater Than 6 Weeks): Chronic fissures with sentinel pile and exposed sphincter fibres rarely heal with dietary modification alone and require active pharmacological or procedural treatment. Topical GTN or diltiazem, botulinum toxin injection, or lateral internal sphincterotomy are appropriate depending on patient preference, symptom severity, and co-existing risk factors for incontinence.
• Patients with Incontinence Risk Factors: Prior obstetric anal sphincter injury, prior anal surgery, Crohn's disease, and baseline faecal incontinence increase the risk of permanent incontinence following lateral internal sphincterotomy. In these patients, botulinum toxin injection is the preferred procedural option, as it carries no permanent sphincter division risk.
• Elderly Patients: Reduced anal sphincter tone with age and potential baseline incontinence symptoms make conservative and pharmacological approaches preferable; sphincterotomy should be considered with caution and after manometric assessment where available.
• Patients Failing Conservative and Pharmacological Treatment: Those who have failed two or more courses of topical pharmacotherapy and botulinum toxin injection are candidates for surgical lateral internal sphincterotomy, which achieves healing rates above 95% and is the definitive treatment for refractory chronic fissures.

Anal fissure treatment follows a well-defined stepwise pathway from conservative to surgical intervention:

• Dietary Modification and Stool Normalisation: The foundation of fissure management. Increasing dietary fibre to 25 to 35 grams per day (fruits, vegetables, whole grains, or psyllium husk supplementation) softens the stool, reducing trauma to the anal mucosa with each bowel movement. Adequate fluid intake (1.5 to 2 litres daily) is essential. Osmotic laxatives (macrogol, lactulose) are used when dietary measures alone are insufficient. Sitz baths — sitting in warm water for 10 to 15 minutes after each bowel movement — promote local hygiene and sphincter relaxation.
• Topical Glyceryl Trinitrate (GTN): A 0.2% to 0.4% GTN ointment applied twice daily to the anal canal releases nitric oxide, causing smooth muscle relaxation of the internal anal sphincter and improving mucosal blood flow. Clinical trials demonstrate healing rates of 50 to 70% for chronic fissures with 8 weeks of treatment. The main side effect is headache (occurring in 20 to 40% of patients), which is usually dose-dependent and may limit compliance. GTN therapy should be applied with a gloved finger or applicator and is continued for 6 to 8 weeks before reassessment.
• Topical Calcium Channel Blockers (Diltiazem or Nifedipine): Topical 2% diltiazem gel or 0.2% nifedipine ointment relaxes the internal sphincter by blocking calcium-dependent smooth muscle contraction. Comparable efficacy to GTN (healing rates 60 to 75%) with a significantly lower incidence of headache, making it the preferred first-line pharmacological agent at many centres. Applied twice daily for 6 to 8 weeks.
• Botulinum Toxin A Injection: Injection of 20 to 30 units of botulinum toxin A (Botox) into the internal anal sphincter produces temporary chemical sphincterotomy lasting 2 to 3 months, allowing fissure healing in 65 to 85% of cases. The procedure is performed under local anaesthesia in the outpatient setting or under sedation. It is particularly valuable in high-risk patients (Crohn's disease, prior sphincter injury, women who have had multiple vaginal deliveries) where permanent surgical sphincterotomy carries elevated continence risk. Fissure recurrence after botulinum toxin occurs in 30 to 40% of patients and can be retreated with a second injection or upgraded to surgical management.
• Lateral Internal Sphincterotomy (LIS): The surgical gold standard for chronic anal fissure refractory to conservative and pharmacological treatment. A portion of the lower internal anal sphincter is divided (either by open or closed lateral approach under local, spinal, or general anaesthesia) to permanently break the spasm cycle. LIS achieves healing rates above 95% with low recurrence. Temporary minor incontinence (flatus, occasional mucus leakage) occurs in 5 to 10% of patients; permanent significant faecal incontinence is reported in 1 to 3% with careful surgical technique limiting sphincterotomy extent.
• Fissurectomy: Surgical excision of the fissure with or without simultaneous sphincterotomy. Used when a large chronic fissure with significant fibrosis, sentinel pile, and hypertrophied papilla is present. Fissurectomy excises the unhealthy scar tissue and converts the wound to fresh edges that heal more readily; often combined with limited sphincterotomy for best outcomes.
• Advancement Flap (Complex or Recurrent Cases): Sliding or island flap procedures using vascularised perianal tissue to cover a non-healing fissure wound are reserved for recurrent fissures after prior sphincterotomy or in Crohn's-associated fissures where repeated sphincter division is contraindicated.

Effective treatment of anal fissures provides significant symptomatic and quality-of-life benefits:

• Rapid Pain Relief: Topical GTN or diltiazem begins reducing internal sphincter pressure within hours of application, with meaningful pain relief evident within the first week of use. Post-defaecatory pain — one of the most debilitating features of chronic fissure — is often the first symptom to improve.
• High Healing Rates with Medical Management: Topical pharmacotherapy achieves healing in 60 to 80% of chronic fissures within 6 to 8 weeks — avoiding the need for surgical intervention in the majority of patients. This represents a substantial advantage of modern medical management over historical approaches that proceeded directly to surgery.
• Outpatient and Non-Invasive Options: Both topical ointments and botulinum toxin injections are outpatient treatments that require no hospitalisation, no general anaesthesia, and minimal recovery time. Patients can continue working and normal daily activities throughout conservative and pharmacological management.
• Definitive Surgical Cure: Lateral internal sphincterotomy offers a greater than 95% long-term healing rate with a low recurrence rate (less than 2%). For patients who have failed medical management, surgery provides a definitive and durable solution to a condition that can cause years of daily discomfort and anxiety around bowel movements.
• Preserved Continence in the Majority: Modern LIS technique, with careful limitation of the length of sphincter divided to the minimum necessary, achieves healing with permanent significant faecal incontinence in only 1 to 3% of cases. The high success rate with minimal functional compromise makes LIS the treatment of choice in refractory cases in suitable patients.
• Improved Quality of Life: The avoidance of painful bowel movements reduces anxiety, fear of defaecation, and constipation caused by voluntary stool retention — a common maladaptive cycle in patients with chronic fissure that worsens the underlying problem. Effective treatment allows return to normal diet, bowel habit, and physical activity.

Each treatment modality for anal fissure carries specific risks that must be discussed with the patient before treatment selection:

• Topical GTN — Headache: The most common adverse effect, occurring in 20 to 40% of patients due to systemic nitrate absorption causing vasodilatory headaches. Headache is typically dose-dependent; using the lowest effective concentration (0.2% vs 0.4%) and applying the ointment perianally rather than inside the anal canal reduces systemic absorption. Concurrent use of phosphodiesterase inhibitors (sildenafil, tadalafil) and nitrates is contraindicated due to risk of severe hypotension.
• Topical Diltiazem — Minor Side Effects: Generally well tolerated. Mild local pruritus or burning occurs in a small proportion of patients. Systemic calcium channel blocker effects (dizziness, flushing) are rare with topical application at standard concentrations.
• Botulinum Toxin — Temporary Incontinence: Temporary impairment of internal sphincter function following botulinum toxin injection causes transient flatus or minor faecal urgency in approximately 5 to 10% of patients during the 2- to 3-month period of pharmacological effect. This resolves spontaneously as the toxin effect wears off and represents a temporary, self-limiting side effect rather than a permanent complication.
• Botulinum Toxin — Recurrence: Fissure recurrence rates following botulinum toxin injection range from 30 to 40%, particularly in patients with underlying chronic constipation or those who do not maintain stool softening measures. Repeat injection is possible; surgical sphincterotomy should be considered after two failed botulinum toxin courses.
• Lateral Internal Sphincterotomy — Incontinence: The most significant and most feared complication of LIS. Minor incontinence (flatus, mucus) occurs in 5 to 10% of patients in the immediate post-operative period and often resolves within 3 to 6 months. Permanent significant faecal incontinence (liquid or solid stool) is reported in 1 to 3% with careful modern surgical technique. Risk is substantially higher in patients with pre-existing sphincter weakness (prior obstetric injury, Crohn's disease, advanced age, prior anal surgery).
• Lateral Internal Sphincterotomy — Surgical Risks: General surgical risks including bleeding, haematoma, wound infection, and non-healing of the sphincterotomy wound are uncommon but possible. Abscess formation at the sphincterotomy site occurs in less than 1% of cases.
• Recurrence After All Treatments: Recurrence of anal fissure is possible after any treatment modality if the underlying cause (constipation, hard stool) is not adequately controlled. Long-term dietary fibre maintenance and stool softening are important regardless of which treatment successfully heals the initial fissure.

Follow-up after anal fissure treatment is important to confirm healing, manage side effects, and prevent recurrence.

• After Starting Topical Pharmacotherapy: A clinical review at 6 to 8 weeks of topical GTN or diltiazem assesses healing progress. If the fissure has healed, pharmacotherapy is gradually tapered and dietary measures are continued long-term. If incomplete healing is documented, the alternative topical agent is tried, or botulinum toxin injection is offered. Patients should continue dietary fibre and stool softeners throughout to support healing and prevent recurrence.
• After Botulinum Toxin Injection: The effect of botulinum toxin takes 2 to 4 weeks to reach full efficacy. A follow-up review at 6 to 8 weeks assesses healing. Most healed fissures are confirmed at the 3-month mark when the toxin effect has fully manifested. Recurrence should prompt discussion of a second injection versus surgical sphincterotomy.
• After Lateral Internal Sphincterotomy: Post-operative care includes twice-daily warm sitz baths, high-fibre diet, oral analgesics, and stool softeners for 2 to 4 weeks. Most patients can return to sedentary work within 1 to 2 weeks. Fissure healing after LIS is confirmed at 4 to 6 weeks post-operatively; complete healing of the skin wound typically occurs by 6 to 12 weeks.
• Long-Term Dietary Maintenance: All patients treated for anal fissure should maintain long-term dietary fibre intake (25 to 35 grams per day) and adequate hydration to prevent stool hardening and recurrence. Psyllium husk supplements are a convenient and evidence-based adjunct for patients who struggle to achieve dietary fibre targets through food alone.
• Monitoring for Recurrence: Any recurrence of characteristic fissure pain (burning post-defaecatory pain) or fresh rectal bleeding should prompt early re-evaluation. Early treatment of recurrent fissures with topical pharmacotherapy reduces the likelihood of progression to chronicity requiring repeat procedural or surgical intervention.
• When to Seek Specialist Review: Patients with atypical fissure features (lateral position, multiple fissures, non-healing despite treatment, systemic symptoms) should be referred for colorectal specialist assessment and investigation for underlying Crohn's disease, sexually transmitted infection, or malignancy before further local treatment is undertaken.

The cost of anal fissure treatment varies by country, chosen modality, and whether conservative, pharmacological, or surgical management is required.

• Conservative and Dietary Management: Dietary fibre supplements and over-the-counter stool softeners are inexpensive (USD 5 to 30 per month) and represent the lowest-cost initial management approach. Warm sitz baths require no additional cost.
• Topical Pharmacotherapy: Topical GTN 0.2% to 0.4% ointment costs USD 20 to 80 per tube depending on the country and whether it is commercially available or compounded by a pharmacy. Topical diltiazem 2% gel is similarly priced. A standard 6 to 8 week treatment course costs USD 40 to 160 including consultation and medication costs in most countries.
• Botulinum Toxin Injection: The procedure cost ranges from USD 300 to 600 in India and Southeast Asia to USD 1,500 to 3,000 in the United States and Australia, including the cost of the botulinum toxin (approximately USD 100 to 400 for the units required), the procedure room, and the clinician fee. The procedure is typically performed in an outpatient setting.
• Lateral Internal Sphincterotomy: Surgical LIS costs approximately USD 500 to 2,000 at private hospitals in India, Thailand, and Malaysia. In Western countries, the procedure costs USD 3,000 to 10,000 including surgical, anaesthesia, and facility fees. It can usually be performed as a day-case (outpatient) procedure, minimising facility costs.
• Country Variation: For patients considering medical travel for botulinum toxin injection or surgical LIS, India, Thailand, and Malaysia offer high-quality outpatient colorectal surgical services at 60 to 80% below Western healthcare pricing. JCI-accredited hospitals in these countries have specialist colorectal surgeons with equivalent training and outcomes to Western centres.
• Insurance Coverage: Botulinum toxin injection and surgical sphincterotomy for medically documented chronic anal fissure are covered by most private health insurance plans and public health systems. Prior authorisation may be required for botulinum toxin in some health systems where it is considered a specialist or off-label use for this indication.

Use MyMedicPlus to find specialist colorectal surgeons and anorectal clinics across more than 40 countries and compare treatment costs for anal fissure management.

Beyond the stepwise conservative-to-surgical pathway, a number of alternative and adjunctive approaches exist for patients who do not respond to or are not suitable for standard treatments:

• Topical Bethanechol: A cholinergic agent that increases acetylcholine-mediated smooth muscle relaxation in the internal sphincter. Small studies report healing rates of 60 to 70% with bethanechol gel applied twice daily, comparable to GTN but without headache. Availability varies by country and it is not universally licensed for this indication.
• Hydrocortisone-Containing Ointments: While commonly self-prescribed for anal discomfort, topical corticosteroids alone do not promote fissure healing and may delay healing if used long-term by suppressing local tissue repair. They have no role in definitive fissure management but may briefly reduce the inflammatory component of acute fissure discomfort when used for a few days.
• Anal Dilatation (Lord's Procedure): Manual dilatation of the anal canal under anaesthesia, previously used as a surgical alternative to sphincterotomy. This procedure is now largely abandoned due to unacceptably high rates of sphincter disruption and subsequent faecal incontinence (reported in up to 27 to 39% of patients in follow-up studies), far exceeding the incontinence risk of contemporary LIS technique.
• Topical Minoxidil: A potassium channel activator causing smooth muscle relaxation. Small-scale studies suggest comparable efficacy to GTN with fewer headache side effects, but evidence is insufficient to recommend it as standard therapy outside of specialist centres and research settings.
• Photodynamic Therapy and Platelet-Rich Plasma: Emerging experimental approaches for chronic non-healing fissures. Limited clinical data exist; these are not currently recommended outside clinical trials.
• Behavioural and Lifestyle Optimisation: For patients with fissures related to bowel habit disorders (irritable bowel syndrome with constipation or diarrhoea, anxiety-related bowel dysfunction), addressing the underlying bowel disorder through dietary changes, gut-directed cognitive behavioural therapy, or low-FODMAP diet provides a sustainable approach to preventing fissure recurrence that pharmacological or surgical treatment alone cannot achieve.